Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Rivaroxaban vs Standard of Care in Moderate to Severe COVID-19
NCT04416048Phase 2Terminated
- Sponsor
- Charité – Universitätsmedizin Berlin
- Start
- Nov 2020
- Primary completion
- Jul 2021
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of rivaroxaban in coronavirus disease 2019 (COVID-19), sponsored by Charité – Universitätsmedizin Berlin. Started Nov 2020; status: terminated.
02
Drugs
rivaroxaban
03
Conditions
coronavirus disease 2019 (COVID-19)
Beyond the preview
Go deeper on NCT04416048.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04416048.